Glowise editorial guide

Can GLP-1 Cause Gastroparesis? What Slower Emptying Does—and Does Not—Mean

Understand the difference between GLP-1-related stomach slowing and gastroparesis, what studies show about risk and recovery, and when symptoms need assessment.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 13, 20267 min read
Download the Glowise App

Share this guide

Xfin
Adult discussing a diagram of the stomach with a healthcare professional in a calm consultation room

GLP-1 medicines can delay stomach emptying, and clinically significant medication-related gastroparesis has been reported. But feeling full sooner, having nausea, or noticing slower digestion does not establish that diagnosis. Gastroparesis requires compatible symptoms, an objective test showing delayed stomach emptying, and exclusion of a physical blockage. It also does not automatically mean permanent damage.

The practical distinction is between an expected medication effect and symptoms that need investigation. Repeated vomiting, difficulty maintaining food or fluids, or stomach symptoms that are severe or do not go away deserve medical attention. You do not need to prove gastroparesis before asking for help.

Slower stomach emptying is an effect; gastroparesis is a diagnosis

Gastric emptying is the movement of a meal from the stomach into the small intestine. GLP-1-based medicines can slow that movement. Tirzepatide, the medicine in Mounjaro and Zepbound, acts on both GIP and GLP-1 receptors; its label says the stomach-emptying delay is greatest after the first dose and diminishes over time. That describes a drug effect, not a guarantee about any person's symptoms. Mounjaro prescribing information.

Gastroparesis is a disorder of stomach movement. The American College of Gastroenterology guideline describes three elements that belong together:

ElementWhat it means
Symptoms consistent with food staying in the stomachThese may include early fullness, prolonged fullness after meals, nausea, vomiting, or upper abdominal discomfort.
Objective delay in emptying solid foodA validated stomach-emptying test documents the delay. Symptoms alone cannot measure it.
No mechanical obstructionAssessment excludes a physical blockage that could explain the retained food or symptoms.

There is overlap: the symptoms of gastroparesis can resemble common digestive side effects or other conditions. A single episode of fullness cannot tell you which explanation applies. Equally, severe symptoms should not be dismissed as evidence that the medicine is simply “working.”

“Stomach paralysis,” a phrase often used in headlines, can make every episode sound like complete, irreversible loss of function. It does not explain how much emptying is delayed, what caused it, or whether it will improve.

What do studies actually show about risk?

The evidence supports taking persistent symptoms seriously. It does not provide one reliable percentage for everyone taking any GLP-1 medicine.

A 2025 retrospective cohort study examined US insurance records for people with obesity without type 2 diabetes who received semaglutide, bupropion-naltrexone, or sleeve gastrectomy. Recorded gastroparesis rates were 6.5, 2.1, and 1.1 cases per 1,000 person-years, respectively. Person-years combine the time people were followed; these figures are not percentages of all users who will develop a lasting disorder.

After adjustment, semaglutide was associated with a higher rate than bupropion-naltrexone: an adjusted hazard ratio of 3.33, with a 95% confidence interval of 2.27–4.98. This was an observational comparison, so differences between treatment groups and other unmeasured factors can affect the result. Insurance diagnoses also cannot establish that every case met standardized emptying-test criteria. The study does not tell us the risk for tirzepatide, for people with diabetes, or the chance of permanent symptoms after stopping treatment.

Trials may answer a different question. A randomized trial involving 72 adults with obesity found no evidence of delayed emptying after 20 weeks of semaglutide escalated to 2.4 mg weekly compared with placebo, using an indirect paracetamol-absorption method. That small trial did not establish that symptomatic gastroparesis never occurs. Its measurement method, selected population, and duration matter when interpreting the finding.

A study of average stomach-emptying behavior and a study of recorded clinical diagnoses can therefore produce different-looking results without settling the same question. Neither supports treating nausea frequency as gastroparesis frequency.

Improvement is possible when the medicine is contributing to delayed emptying. A published report of two patients with type 2 diabetes described resolution of symptoms and normalization of repeat stomach-emptying studies after semaglutide was withheld for six weeks in one patient and dulaglutide for four weeks in the other.

Those are individual cases, not a recovery schedule. They show that reversible medication-related delay can occur; they cannot establish how often it resolves, how long everyone needs, or whether a particular person's symptoms come entirely from the medicine.

Diabetes itself can cause gastroparesis, and other causes may coexist. A clinician has to consider the symptoms before treatment, their timing after starting or changing medication, other medicines, and the test results. Drug clearance and recovery are also different questions: knowing how long a medicine remains in the body does not prove when a person's eating, symptoms, or stomach-emptying test will return to normal.

Symptoms that continue after a clinician changes treatment deserve reassessment. Persistence does not, by itself, prove permanent GLP-1 injury or rule out another condition.

What do current US labels say?

Current US prescribing information for Wegovy, Ozempic, Mounjaro, and Zepbound says these products are not recommended in patients with severe gastroparesis. This is a specific warning; it is not a statement that everyone who feels full has gastroparesis, nor a blanket contraindication covering every digestive symptom.

If you already have gastroparesis or are being evaluated for it, tell the prescriber before treatment decisions are made. If symptoms develop during treatment, contact the prescribing team for assessment and a medication plan. A clinician may decide that changing or discontinuing a contributing medicine is appropriate, while arranging an alternative plan for the condition it was treating.

Do not use an online washout schedule or an improved day as instructions to stop, restart, or increase a dose. The urgent pancreatitis directions below are a separate, explicit label instruction.

What an evaluation may involve

The first useful information is a clear timeline: when symptoms began, whether they predated the medicine, the product and dose, recent changes, vomiting episodes, and whether you can keep food and fluids down. Bring a full medication list. This helps distinguish a possible medication effect from other explanations; it does not diagnose the cause.

Depending on the situation, a clinician may use blood tests, imaging, or upper endoscopy to investigate other causes and exclude obstruction. A gastric-emptying study then addresses a different question: how quickly does a standardized meal leave the stomach? NIDDK explains the diagnostic assessment.

The 2025 American Gastroenterological Association guideline favors a four-hour emptying study over a two-hour or shorter study. It also emphasizes avoiding confounding from high blood glucose and medicines that alter emptying, including GLP-1 medicines, opioids, and medicines that speed stomach movement.

Ask the ordering team how to prepare and how they will account for your medicines and diabetes, if applicable. Let them set any withholding instructions. A delayed result obtained while taking a medicine that slows emptying needs that context; the result alone cannot establish a permanent disorder independent of treatment.

If gastroparesis is confirmed, care may address hydration, nutrition, glucose management where relevant, contributing medicines, and treatments for symptoms or stomach movement. These choices depend on the cause and severity. Ordinary nausea remedies are not a substitute for that evaluation.

When to get help promptly

Tell your prescribing team about stomach symptoms that are severe or will not go away. The Medication Guides also direct patients to contact their healthcare provider right away for nausea, vomiting, or diarrhea that does not go away: fluid loss can lead to kidney problems. Seek prompt assessment if repeated vomiting or prolonged fullness is making it difficult to eat or maintain fluids, especially with reduced urination or dizziness.

NIDDK advises seeking medical help right away for vomiting lasting more than an hour, severe abdominal pain or cramping, sudden sharp stomach pain that does not go away, blood or coffee-ground material in vomit, extreme weakness or fainting, difficulty breathing, fever, or blood glucose that is too high or too low. Call 911 for severe breathing difficulty, collapse, or another life-threatening emergency. Do not wait for an outpatient emptying test when urgent symptoms are present.

There is also an important medication-specific action: the US labels for Wegovy, Ozempic, Mounjaro, and Zepbound instruct patients to stop the medicine and contact their healthcare provider right away if pancreatitis is suspected, including severe abdominal pain that will not go away, sometimes extending to the back, with or without nausea or vomiting. Do not label that pattern “gastroparesis” and keep taking doses while waiting. See the Wegovy Medication Guide and the Zepbound Medication Guide.

You can take digestive symptoms seriously without naming the diagnosis yourself. The useful next step is to describe what is happening, protect your ability to eat and drink, and get the assessment that separates a medication effect from a condition needing treatment.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.